Clinical trial
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by…
NCT00166296 · Germans Trias i Pujol Hospital, Other · Completed
Key facts
| NCT number | NCT00166296 |
|---|---|
| Title | Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients |
| Official title | Study of the Efficacy and Safety of Escitalopram for the Prevention of Depressive Episodes Induced by Peg-Interferon Alpha2a and Ribavirin in Chronic Hepatitis C Patients. Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| Lead sponsor | Germans Trias i Pujol Hospital, Other |
| Collaborators | Hoffmann-La Roche Industry H. Lundbeck A/S |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder, Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Escitalopram, Placebo |
| Enrollment | 133 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | Aug 17, 2020 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: